Delving into the Latest Updates on Erythropoietin(Stem Cell Therapeutics) with Synapse

Overview

Basic Info

Drug Type

Colony-stimulating factors

Synonyms-

Target

EPO receptor

Action

agonists

Mechanism

EPO receptor agonists(Erythropoietin receptor agonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication-

Inactive Indication

Stroke

Originator Organization

Stem Cell Therapeutics

Active Organization-

Inactive Organization

Stem Cell Therapeutics

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) may support hemodynamics of patients experiencing cardiogenic shock refractory to medical management. We present a 62-year-old Jehovah's Witness female with a history of smoking, obstructive sleep apnea, and anemia presenting with acute myocardial infarction and ensuing cardiogenic shock that required V-A ECMO support due to persistent hemodynamic instability and hypoxemia. Meticulous care to blood saving strategies were employed contributing to the successful management of the patient. These strategies included minimizing frequency of laboratory testing, use of micro-pediatric tubes, meticulous tissue handling to minimize blood loss during decannulation and administration of supplementary agents (vitamin B12, folic acid, iron, and erythropoietin) in consideration with the ethical concerns of the patients and their family. During the patient's hospital stay, their hemoglobin decreased from 14.6 mg/dL to as low as 7.6 mg/dL 3 days after decannulation. To our knowledge, this is the third reported case of V-A ECMO support in a Jehovah's Witness patient and the first reported critical care case. In conclusion, employing a bloodless strategy and adhering to recommended practices can yield positive outcomes for patients who do not accept blood transfusions requiring V-A ECMO.

01 Apr 2025·JOURNAL OF ARTHROPLASTY

Bloodless Total Hip Arthroplasty in Jehovah’s Witness Patients: Contemporary Strategies and Outcomes

Article

Author: Ohanisian, Levonti ; Miranda, Michael ; Bernasek, Thomas ; Bernasek, Thomas L ; Salomon, Kevin ; Miranda, Michael A ; Ohanisian, Levonti L ; Simon, Peter ; Shen, Victor ; Salomon, Kevin I

BACKGROUND:

Reported blood transfusion rates in total hip arthroplasty (THA) range between 3 and 22%. Jehovah's Witnesses (JW) do not accept blood transfusions and make conscience decisions to accept blood derivatives. This study reports on strategies and outcomes for bloodless THA.

METHODS:

All JW patients undergoing primary THA at our institution between 2011 and 2022 were included in this study (94 of 110 THA). The indications for THA were osteoarthritis (92%), femoral neck fracture (6%), rheumatoid arthritis (1%), and failed open reduction and internal fixation (1%). Strategies used to optimize outcomes included erythropoietin, tranexamic acid, cell savers, intrailiac artery tourniquets, and minimizing phlebotomy.

RESULTS:

The mean estimated blood loss was 201.2 ± 122.2 mL. Preoperative hemoglobin (Hgb) levels were 13.4 ± 1.4 g/dL, which decreased to 11.0 ± 1.3 g/dL on postoperative day 1 (POD1, P < 0.001), 10.3 ± 1.5 g/dL on POD2 (P = 0.001), and 9.8 ± 1.1 g/dL on POD3 (P = 0.171). The use of tranexamic acid significantly decreased Hgb drop on POD1 (P = 0.04). Subgroup analysis showed that preoperatively anemic patients (closed circuit, Hgb < 12 g/dL) had significantly less Hgb drop postoperatively (P = 0.003). No patients met the recommended transfusion threshold (Hgb < 7 g/dL). There were two 90-day readmissions due to falls. There was zero 90-day mortality.

CONCLUSIONS:

A THA can be safely performed on JW patients. Preoperatively anemic patients had a decreased Hgb drop postoperatively. JW patients make a conscious decision to accept blood derivatives, which may be present in medications including erythropoietin. We recommend maintaining an Hgb above 11 g/dL prior to surgery, as a Hgb drop of 3.1 g/dL can be expected. These findings highlight the efficacy of a multimodal approach to optimizing bloodless primary THAs.

01 Apr 2025·BRITISH JOURNAL OF OPHTHALMOLOGY

Traumatic Optic Neuropathy Treatment Trial 2 (TONTT-2): evaluating the efficacy of different doses of erythropoietin – a multicentre, randomised, double-blind clinical trial

Article

Author: Kashkouli, Mohsen Bahmani ; Pakdel, Farzad ; Nojomi, Marzieh ; Ghahvehchian, Hossein ; Ghazizadeh, Mahya ; Abdolalizadeh, Parya ; Abri Aghdam, Kaveh ; Etezad Razavi, Mohammad ; Karimi, Nasser ; Sanjari, Mostafa Soltan ; Soleimani, Mohammad ; Tabatabaei, Seyed Ali

Aim:

The aim is to compare the efficacy and safety of three different weight-adjusted intravenous erythropoietin (EPO) doses in patients with indirect traumatic optic neuropathy (TON).

Methods:

This study is a multicentre, randomised, parallel-group, double-blind, dose-finding trial on patients aged ≥7 years with a confirmed diagnosis of indirect TON in ≤3 weeks. The trial had a 3-day treatment period and a 3-month follow-up period. Patients were randomly allocated (1:1:1) to receive EPO at doses of 900 IU/kg (300 IU/kg/day), 1800 IU/kg (600 IU/kg/day) or 3600 IU/kg (600 IU/kg/day on presentation and then 1 month later) EPO. The changes in the best-corrected visual acuity (BCVA), colour vision and relative afferent pupillary defect (RAPD) were assessed.

Results:

Out of 118 eligible patients, 95 were randomised and 93 (31 in each group) completed the follow-ups. Three groups were not different regarding baseline BCVA (p=0.66), colour vision (p=0.25) and RAPD (p=0.79). All three groups showed a significant improvement of BCVA and RAPD with no significant differences among the groups. Colour vision showed a significant improvement only in the group with 3600 IU/kg EPO (p=0.005), even though final colour vision was not significantly different between the groups (p=0.49). Initial vision of no light perception (OR=7.79 (95% CI: 2.98 to 20.36), p<0.001), older age (OR=4.76 (95% CI: 1.92 to 11.76), p<0.001), longer trauma-treatment interval (OR=2.72, 95% CI: 1.16 to 6.33, p=0.02) and posterior orbital fractures (OR=2.63 (95% CI: 1.13 to 6.13), p=0.02) led to a significantly worse visual recovery.

Conclusion:

Increasing dose of EPO in patients with TON did not result in a better BCVA, colour vision and RAPD improvement.

Trial registration number:

NCT03308448.

100 Deals associated with Erythropoietin(Stem Cell Therapeutics)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stroke	Phase 2	United States	Stem Cell Therapeutics	01 Aug 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2024	Not Applicable	Myelodysplastic Syndromes SF3B1 mutation	54	Luspatercept + ESA	kxnfzshpps(pcnbpddyyy) = Luspatercept was very well tolerated without any adverse event higher then Gr II toxicity ccyuuvfhuh (wfsfeoygic )	Positive	14 May 2024
EHA2024	Not Applicable	Myelodysplastic Syndromes	228	Erythropoietin stimulating agents (ESAs)	xmrqywqlfr(qqpvaucgyi) = zggdzszzzd pmyzcuziyp (ygcrntzfgm )	-	14 May 2024
ISN WCN2024	Not Applicable	-	-	Erythropoietin dose reduction	wvdghhfnyr(jagvxjxegk) = ryohahqama mvqinaqlub (ucbpxehkbt )	-	01 Apr 2024
				Standard Erythropoietin dose	wvdghhfnyr(jagvxjxegk) = vlxvwzdwxz mvqinaqlub (ucbpxehkbt )
EUMDS Registry (EHA2022)	Not Applicable	Myelodysplastic Syndromes	2,562	ESA treated	woxpqynnlq(blxyjgdpma) = hoyazjcekx qbvopafywk (zsugzjohim )	-	12 May 2022
				ESA untreated	woxpqynnlq(blxyjgdpma) = lbjjcfdnat qbvopafywk (zsugzjohim )
ISN WCN2022	Not Applicable	-	-	ERYTHROPOIETIN (Pre-remedial)	pdzzswbhep(qtioclfoqv) = erratic avvguvsfew (powyzphcgp ) View more	-	01 Feb 2022
				ERYTHROPOIETIN (Post-remedial)
ISN WCN2020	Not Applicable	Maintenance TSAT \| serum ferritin	330	IV ferrous sucrose 100 mg	scubyneniw(qnxjlavycv) = tqlzomwign cainqesqwg (aqikwdwlhe, 21)	Positive	01 Mar 2020
SP422 (ERA2019)	Not Applicable	Hemodialysis complication Maintenance	158	erythropoietin (Lower ERI)	massxxwyol(khxgezpsel) = pbwqdtajre kvpisqdxxo (ovjlszcixu )	Positive	13 Jun 2019
				erythropoietin (Higher ERI)	massxxwyol(khxgezpsel) = wkufpmwagp kvpisqdxxo (ovjlszcixu )
EHA2019	Not Applicable	Myelodysplastic Syndromes	177	Erythropoietin	ngquublycv(jbqmlyjpgh) = yoksdkvtdd ihyqlzbijl (wxwqbhixhc ) View more	-	16 May 2019
				Erythropoietin (Pack cell transfusion)	ngquublycv(jbqmlyjpgh) = jazmpdzmrn ihyqlzbijl (wxwqbhixhc ) View more
EHA2019	Not Applicable	Myelodysplastic Syndromes	45	Group A (sodium ferrigluconate)	nzybdbhawx(bqnaxwxqqq) = osvmzuecmn mrqzowdbrf (mzesltcnqh ) View more	-	16 May 2019
				Group B (sucrosomial iron)	nzybdbhawx(bqnaxwxqqq) = ckwnnuknry mrqzowdbrf (mzesltcnqh ) View more
ASGCT2018	Not Applicable	-	-	Erythropoietin	sosckxafdh(wjcjbzbbpu) = ktftwjqtcl megvffqcxg (imlmucuulm )	-	01 May 2018
				Tmprss6-Antisense Oligonucleotides	sosckxafdh(wjcjbzbbpu) = kizilpatuj megvffqcxg (imlmucuulm )

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data